{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-069212","form_type":"8-K","ticker":"ERAS","cik":"0001761918","company_name":"Erasca, Inc.","filed_at":"2023-12-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.349342+00:00","generated_at":"2026-06-07T14:59:13.608417+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Erasca receives FDA Fast Track Designation for naporafenib combo in NRAS-mutant melanoma","bullets":["FDA granted Fast Track Designation to naporafenib + trametinib for unresectable/metastatic NRASm melanoma after PD-(L)1 failure.","FTD facilitates development and expedites review for drugs addressing unmet medical needs.","Benefits include more frequent FDA interactions and potential rolling submission of marketing application.","Naporafenib (ERAS-007) is an oral pan-RAF inhibitor; trametinib is a MEK inhibitor already marketed as MEKINIST."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-069212","json":"https://secwatch.observer/filing/0000950170-23-069212.json","markdown":"https://secwatch.observer/filing/0000950170-23-069212.md","text":"https://secwatch.observer/filing/0000950170-23-069212.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1761918/000095017023069212/0000950170-23-069212-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1761918/000095017023069212/eras-20231211.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T14:59:13.608417+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}